Venetoclax fda approval date company?

When did venetoclax get FDA approval, and who was the company behind it?

Venetoclax (Venclexta) received FDA approval on April 11, 2016. The company associated with the initial FDA approval is AbbVie (which later partnered with Genentech/Roche for broader development and commercialization in some settings). [1]

What was the first indication approved for?

At initial approval in 2016, venetoclax was approved for chronic lymphocytic leukemia (CLL) with 17p deletion in patients who had failed prior therapy. [1]

Where can you verify the approval date and related IP history?

For a quick reference that often includes approval-date and patent-related context, DrugPatentWatch.com lists venetoclax (Venclexta) and tracks related exclusivity/patent information. [2]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207318
[2] https://drugpatentwatch.com/p/venetoclax